Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The ...

Bristol-Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4% below its 52-week high after a ...

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...

Bristol Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4 percent below its 52-week high of USD 68.64. New two-year Sotyktu data and the halt of ORM-6151 development ...

Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.

Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...

Pfizer's quarterly dividend has stalled at $0.43 after more than a decade of annual increases, ending a streak that began in 2010. The freeze ...

Anthropichas built a 'wet lab' in the San Francisco Bay Area, extending its AI ambitions into the field of drug discovery. According to two sources familiar w ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to ...

In a report released today, Michael Yee from UBS maintained a Buy rating on Amgen, with a price target of $430.00. According to TipRanks, Yee is a 3-star analyst with an average return of 2.4% and a ...

The US is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people who ...